New Insights in Mechanisms and Therapeutics for Short- and Long-Term Impacts of Hepatic Ischemia Reperfusion Injury Post Liver Transplantation.

Abstract

Liver transplantation has been identified as the most effective treatment for patients with end-stage liver diseases. However, hepatic ischemia reperfusion injury (IRI) is associated with poor graft function and poses a risk of adverse clinical outcomes post transplantation. Cell death, including apoptosis, necrosis, ferroptosis and pyroptosis, is induced during the acute phase of liver IRI. The release of danger-associated molecular patterns (DAPMs) and mitochondrial dysfunction resulting from the disturbance of metabolic homeostasis initiates graft inflammation. The inflammation in the short term exacerbates hepatic damage, leading to graft dysfunction and a higher incidence of acute rejection. The subsequent changes in the graft immune environment due to hepatic IRI may result in chronic rejection, cancer recurrence and fibrogenesis in the long term. In this review, we mainly focus on new mechanisms of inflammation initiated by immune activation related to metabolic alteration in the short term during liver IRI. The latest mechanisms of cancer recurrence and fibrogenesis due to the long-term impact of inflammation in hepatic IRI is also discussed. Furthermore, the development of therapeutic strategies, including ischemia preconditioning, pharmacological inhibitors and machine perfusion, for both attenuating acute inflammatory injury and preventing late-phase disease recurrence, will be summarized in the context of clinical, translational and basic research.

• Authors: Hui Liu, Kwan Man
• Journal: International journal of molecular sciences (Int J Mol Sci) Vol. 22 Issue 15 (Jul 30 2021) ISSN: 1422-0067 [Electronic] Switzerland
• PMID: 34360975 (Publication Type: Journal Article, Review)

Chemical References

• Prostaglandins

Topics

• Animals
• Humans
• Ischemic Preconditioning (methods)
• Liver (blood supply, metabolism)
• Liver Transplantation (adverse effects)
• Postoperative Complications (drug therapy, metabolism, therapy)
• Primary Graft Dysfunction (drug therapy, metabolism, therapy)
• Prostaglandins (therapeutic use)